Precision BioSciences Inc. released its financial results for the quarter ended March 31, 2025, showing a significant decline in total revenues to less than $0.1 million from $17.6 million in the same quarter the previous year. This decrease was primarily attributed to the conclusion of revenue recognition from agreements with TG Therapeutics, Caribou Biosciences, and Prevail, as well as nearing completion of the workplan under the Novartis Agreement. The company reported a net loss of $20.6 million for the quarter, in contrast to a net income of $8.6 million in the previous year. Research and development expenses slightly increased to $13.6 million, up from $13.3 million for the same quarter in 2024, mainly due to the advancement of the PBGENE-DMD program. General and administrative expenses also saw a minor increase to $8.6 million from $8.4 million, driven by employee-related costs. Significant business updates include new clinical data validating the safety and efficacy of Precision's in vivo gene editing approach and initial data from the Phase 1 ELIMINATE-B trial for PBGENE-HBV. The company received regulatory clearance to expand the trial in the U.S. and the UK, along with a Fast Track Designation for PBGENE-HBV for chronic Hepatitis B. The PBGENE-DMD program is being accelerated to address Duchenne's Muscular Dystrophy, with plans to file IND/CTA in 2025 and present clinical data in 2026. Precision believes its current cash position is sufficient to support these advancements into the second half of 2026.